Mölndal, Sweden

Matti Juhani Lepisto


Average Co-Inventor Count = 7.4

ph-index = 6

Forward Citations = 256(Granted Patents)


Location History:

  • 73 Lund, SE (1999)
  • Lund, SE (2000 - 2011)
  • Molndal, SE (2017)
  • Mölndal, SE (2021)

Company Filing History:


Years Active: 1999-2021

Loading Chart...
12 patents (USPTO):Explore Patents

Title: **Innovator Spotlight: Matti Juhani Lepisto**

Introduction

Matti Juhani Lepisto is a distinguished inventor based in Mölndal, Sweden, recognized for his significant contributions to the field of pharmaceuticals. With a portfolio of 12 patents, Lepisto has made considerable strides in the development of innovative compounds aimed at treating various medical conditions.

Latest Patents

Among his latest inventions are JAK1 selective inhibitors, which involve the disclosure of compounds represented by a specific formula, along with their pharmaceutically acceptable salts. These compounds are crucial in the formulation of pharmaceutical compositions and their associated methods of use. Additionally, he has developed phenyl and benzodioxinyl substituted indazoles derivatives. This invention relates to novel indazolyl derivatives and includes pharmaceutical compositions and processes for their preparation, emphasizing their potential as medicaments.

Career Highlights

Lepisto has a rich career background that includes working with reputable organizations such as Siga Pharmaceuticals, Inc. and Washington University. His professional journey has been marked by a strong commitment to innovation and research in medicinal chemistry.

Collaborations

Throughout his career, Lepisto has collaborated with notable individuals in the field. Among his coworkers are Scott J. Hultgren and Meta Kuehn, both of whom have likely contributed to his research and patent developments.

Conclusion

Matti Juhani Lepisto's innovative spirit and dedication to pharmaceutical research have positioned him as an influential figure in the industry. His patents not only contribute to scientific advancement but also hold the promise of improved treatment options for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…